One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Adagene  logo
Adagene ADAG
$ 2.29 0.54%
report update icon

Quarterly report 2025-Q4
added 07-06-2026

Adagene Financial Ratios 2025-2011 | ADAG

Brief overview of Adagene 's valuation multiples

The comparison uses the five latest available annual observations between 2021 and 2025.

The valuation comparison uses P/S 35.6x (median 40.44x), P/B 4.32x (median 2.05x). Valuation is 49.5% above five-year reference levels. The premium requires support from earnings and returns.

Capital efficiency is characterized by ROE -49.8%, ROA -22.5%, ROCE -46.2%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.

Current PEG is 0.61x; the market pays comparatively little per unit of expected growth.

The time from paying for inputs to receiving cash fell from 182.5 days to 53.8 days. Cash turnover improved.

Overall assessment

Adagene 's multiples are demanding relative to current business quality. Material improvement is needed to justify them.

Annual Financial Ratios Adagene

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-12.7 -2.6 -7.6 -0.8 -5.0 -0.7 -1.6 -1.1 - - - - - - -

P/S

29.2 850.8 8.0 6.7 35.6 45.3 53.8 11.5 - - - - - - -

EPS

-0.3 -0.6 -0.3 -1.5 -1.5 -2.7 -1.1 -0.9 - - - - - - -

EV (Enterprise Value)

176 M 41.4 M 79.7 M -12.2 M 395 M -24.2 M -58 M 96.8 M - - - - - - -

EBITDA per Share

-0.36 -0.63 -0.42 -1.53 -1.42 -2.65 -1.21 -1.08 - - - - - - -

EV/EBITDA

-8.4 -1.2 -3.5 0.1 -4.9 - - - - - - - - - -

PEG

0.61 -0.23 -1.92 - - - - - - - - - - - -

P/B

4.3 1.7 2.0 0.7 2.3 0.5 0.3 -0.4 - - - - - - -

P/CF

-14.3 -3.0 -5.1 -1.3 -8.3 -1.1 -1.4 -1.2 - - - - - - -

ROE %

-49.82 -66.16 -26.85 -96.25 -46.74 47.43 28.82 37.21 - - - - - - -

ROA %

-22.50 -37.44 -16.37 -52.48 -38.61 -50.32 -15.52 -28.05 - - - - - - -

ROCE %

-60.65 -71.16 -33.62 -101.00 -46.22 -63.35 -19.42 -39.33 - - - - - - -

Current Ratio

3.0 2.3 2.6 2.2 5.8 4.4 12.2 0.6 - - - - - - -

DSO

- - - 58.9 53.8 125.0 182.5 - - - - - - - -

Operating Cycle

- - - 58.9 53.8 125.0 182.5 - - - - - - - -

Cash Conversion Cycle

- - - 58.9 53.8 125.0 182.5 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Adagene

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.3 -0.23 -0.59 -0.31 -0.35 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.36 -0.26 -0.63 -0.32 -0.42 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-181.58 -158.62 -66.16 -30.06 -26.85 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-97.08 -90.96 -37.44 -16.88 -16.37 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-205.56 -178.53 -71.16 -32.38 -33.62 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

3.0 2.3 2.3 2.3 2.6 - - - - 5.8 - - - 4.4 - - - 12.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Adagene , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
$ 1.21 5.22 % $ 7.62 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.12 1.82 % $ 112 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.37 0.75 % $ 3.7 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 58.37 0.41 % $ 7.81 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 55.14 1.4 % $ 10.6 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.84 0.46 % $ 1.85 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.13 4.42 % $ 50.4 M israelIsrael
Jaguar Health Jaguar Health
JAGX
$ 4.18 0.48 % $ 9.75 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.61 0.36 % $ 205 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
$ 20.97 1.72 % $ 1.21 B niderlandNiderland
Stoke Therapeutics Stoke Therapeutics
STOK
$ 23.26 3.38 % $ 1.38 B usaUSA
Xencor Xencor
XNCR
$ 23.39 0.17 % $ 1.74 B usaUSA
Annexon Annexon
ANNX
$ 3.67 0.52 % $ 569 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.93 1.54 % $ 3.18 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
$ 111.57 2.72 % $ 21.8 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 13.79 0.11 % $ 16.7 B australiaAustralia
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 9.41 0.28 % $ 757 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 498.5 2.74 % $ 127 B usaUSA
AbbVie AbbVie
ABBV
$ 283.48 3.32 % $ 501 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 4.36 0.1 % $ 231 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.38 1.11 % $ 414 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.19 1.95 % $ 803 M canadaCanada
Inozyme Pharma Inozyme Pharma
INZY
- - $ 207 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 7.0 0.21 % $ 305 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA